

Publications

1. M. Hornburg, M. Desbois, S. Lu, Y. Guan, A. A. Lo, S. Kaufman, A. Elrod, A. Lotstein, T. M. DesRochers, J. L. Munoz-Rodriguez, X. Wang, J. Giltane, O. Mayba, S. J. Turley, R. Bourgon, A. Daemen, Y. Wang, Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. *Cancer cell* **39**, 928-944.e926 (2021).
2. S. P. Hack, W. Verret, S. Mulla, B. Liu, Y. Wang, T. Macarulla, Z. Ren, A. B. El-Khoueiry, A. X. Zhu, IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. *Therapeutic advances in medical oncology* **13**, 17588359211036544 (2021).
3. M. Desbois, Y. Wang, Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. *Immunological reviews* **302**, 241-258 (2021).
4. K. N. Moore, M. J. Birrer, J. Marsters, Y. Wang, Y. Choi, S. Royer-Joo, V. Lemahieu, K. Armstrong, J. Cordova, D. Samineni, E. Schuth, A. Vaze, D. Maslyar, E. W. Humke, E. P. Hamilton, J. F. Liu, Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. *Gynecologic oncology* **158**, 631-639 (2020).
5. S. Lu, C. J. Chang, Y. Guan, E. Szafer-Glusman, E. Punnoose, A. Do, B. Suttman, R. Gagnon, A. Rodriguez, M. Landers, J. Spoerke, M. R. Lackner, W. Xiao, Y. Wang, Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level. *J Mol Diagn* **22**, 770-781 (2020).
6. M. S. Lee, B. Y. Ryoo, C. H. Hsu, K. Numata, S. Stein, W. Verret, S. P. Hack, J. Spahn, B. Liu, H. Abdullah, Y. Wang, A. R. He, K. H. Lee, Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. *The Lancet. Oncology* **21**, 808-820 (2020).
7. S. P. Hack, A. X. Zhu, Y. Wang, Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. *Frontiers in immunology* **11**, 598877 (2020).
8. D. E. Gerber, J. R. Infante, M. S. Gordon, S. B. Goldberg, M. Martín, E. Felip, M. Martinez Garcia, J. H. Schiller, D. R. Spigel, J. Cordova, V. Westcott, Y. Wang, D. S. Shames, Y. Choi, R. Kahn, R. C. Dere, D. Samineni, J. Xu, K. Lin, K. Wood, S. Royer-Joo, V. Lemahieu, E. Schuth, A. Vaze, D. Maslyar, E. W. Humke, H. A. Burris, 3rd, Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **26**, 364-372 (2020).
9. R. S. Finn, S. Qin, M. Ikeda, P. R. Galle, M. Ducreux, T. Y. Kim, M. Kudo, V. Breder, P. Merle, A. O. Kaseb, D. Li, W. Verret, D. Z. Xu, S. Hernandez, J. Liu, C. Huang, S. Mulla, Y. Wang, H. Y. Lim, A. X. Zhu, A. L. Cheng, Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *The New England journal of medicine* **382**, 1894-1905 (2020).
10. M. Desbois, A. R. Udyavar, L. Ryner, C. Kozlowski, Y. Guan, M. Dürrbaum, S. Lu, J. P. Fortin, H. Koeppen, J. Ziai, C. W. Chang, S. Keerthivasan, M. Plante, R. Bourgon, C. Bais, P. Hegde, A. Daemen, S. Turley, Y. Wang, Integrated digital pathology and

- transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. *Nature communications* **11**, 5583 (2020).
11. J. F. Liu, M. Gordon, J. Veneris, F. Braiteh, A. Balmanoukian, J. P. Eder, A. Oaknin, E. Hamilton, Y. Wang, I. Sarkar, L. Molinero, M. Fassò, C. O'Hear, Y. G. Lin, L. A. Emens, Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. *Gynecologic oncology* **154**, 314-322 (2019).
 12. L. Crisafulli, S. Muggeo, P. Uva, Y. Wang, M. Iwasaki, S. Locatelli, A. Anselmo, F. S. Colombo, C. Carlo-Stella, M. L. Cleary, A. Villa, B. Gentner, F. Ficara, MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation. *Haematologica* **104**, 1744-1755 (2019).
 13. S. Mariathasan, S. J. Turley, D. Nickles, A. Castiglioni, K. Yuen, Y. Wang, E. E. Kadel, III, H. Koeppen, J. L. Astarita, R. Cubas, S. Jhunjhunwala, R. Banchereau, Y. Yang, Y. Guan, C. Chalouni, J. Ziai, Y. Şenbabaoğlu, S. Santoro, D. Sheinson, J. Hung, J. M. Giltane, A. A. Pierce, K. Mesh, S. Lianoglou, J. Riegler, R. A. D. Carano, P. Eriksson, M. Höglund, L. Somarriba, D. L. Halligan, M. S. van der Heijden, Y. Loriot, J. E. Rosenberg, L. Fong, I. Mellman, D. S. Chen, M. Green, C. Derleth, G. D. Fine, P. S. Hegde, R. Bourgon, T. Powles, TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* **554**, 544-548 (2018).
 14. S. Banerjee, A. M. Oza, M. J. Birrer, E. P. Hamilton, J. Hasan, A. Leary, K. N. Moore, B. Mackowiak-Matejczyk, J. Pikiel, I. Ray-Coquard, P. Trask, K. Lin, E. Schuth, A. Vaze, Y. Choi, J. C. Marsters, D. J. Maslyar, V. Lemahieu, Y. Wang, E. W. Humke, J. F. Liu, Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. *Ann Oncol*, (2018).
 15. Y. Guan, O. Mayba, T. Sandmann, S. Lu, Y. Choi, W. C. Darbonne, V. Leveque, L. Ryner, E. Humke, N. W. R. Tam, S. Sujathasarma, A. Cheung, R. Bourgon, M. R. Lackner, Y. Wang, High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing. *J Mol Diagn* **19**, 921-932 (2017).
 16. C. D. Weekes, L. E. Lamberts, M. J. Borad, J. Voortman, R. R. McWilliams, J. R. Diamond, E. G. de Vries, H. M. Verheul, C. H. Lieu, G. P. Kim, Y. Wang, S. J. Scales, D. Samineni, F. Brunstein, Y. Choi, D. J. Maslyar, G. Colon-Otero, Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. *Molecular cancer therapeutics* **15**, 439-447 (2016).
 17. T. Powles, M. R. Lackner, S. Oudard, B. Escudier, C. Ralph, J. E. Brown, R. E. Hawkins, D. Castellano, B. I. Rini, M. D. Staehler, A. Ravaud, W. Lin, B. O'Keeffe, Y. Wang, S. Lu, J. M. Spoerke, L. Y. Huw, M. Byrtek, R. Zhu, J. A. Ware, R. J. Motzer, Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **34**, 1660-1668 (2016).
 18. V. Makker, F. O. Recio, L. Ma, U. A. Matulonis, J. O. Lauchle, H. Parmar, H. N. Gilbert, J. A. Ware, R. Zhu, S. Lu, L. Y. Huw, Y. Wang, H. Koeppen, J. M. Spoerke, M. R. Lackner, C. A. Aghajanian, A multicenter, single-arm, open-label, phase 2 study of

- apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). *Cancer* **122**, 3519-3528 (2016).
19. J. F. Liu, K. N. Moore, M. J. Birrer, S. Berlin, U. A. Matulonis, J. R. Infante, B. Wolpin, K. A. Poon, R. Firestein, J. Xu, R. Kahn, Y. Wang, K. Wood, W. C. Darbonne, M. R. Lackner, S. K. Kelley, X. Lu, Y. J. Choi, D. Maslyar, E. W. Humke, H. A. Burris, Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. *Ann Oncol* **27**, 2124-2130 (2016).
 20. L. Ryner, Y. Guan, R. Firestein, Y. Xiao, Y. Choi, C. Rabe, S. Lu, E. Fuentes, L. Y. Huw, M. R. Lackner, L. Fu, L. C. Amler, C. Bais, Y. Wang, Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **21**, 2941-2951 (2015).
 21. G. D. Meredith, A. D'Ippolito, M. Dudas, L. C. Zeidner, L. Hostetter, K. Faulds, T. H. Arnold, A. P. Popkie, B. W. Doble, G. Marnellos, C. Adams, Y. Wang, C. J. Piel, Glycogen synthase kinase-3 (Gsk-3) plays a fundamental role in maintaining DNA methylation at imprinted loci in mouse embryonic stem cells. *Molecular biology of the cell* **26**, 2139-2150 (2015).
 22. C. E. Briggs, Y. Wang, B. Kong, T. U. Woo, L. K. Iyer, K. C. Sonntag, Midbrain dopamine neurons in Parkinson's disease exhibit a dysregulated miRNA and target-gene network. *Brain research* **1618**, 111-121 (2015).
 23. W. Zhou, A. M. Jubb, K. Lyle, Q. Xiao, C. C. Ong, R. Desai, L. Fu, F. Gnad, Q. Song, P. M. Haverty, D. Aust, R. Grützmann, M. Romero, K. Totpal, R. M. Neve, Y. Yan, W. F. Forrest, Y. Wang, R. Raja, C. Pilarsky, A. de Jesus-Acosta, M. Belvin, L. S. Friedman, M. Merchant, E. M. Jaffee, L. Zheng, H. Koeppen, K. P. Hoeflich, PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. *The Journal of pathology* **234**, 502-513 (2014).
 24. W. Kim, Y. Lee, N. D. McKenna, M. Yi, F. Simunovic, Y. Wang, B. Kong, R. J. Rooney, H. Seo, R. M. Stephens, K. C. Sonntag, miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. *Neurobiol Aging* **35**, 1712-1721 (2014).
 25. R. Bourgon, S. Lu, Y. Yan, M. R. Lackner, W. Wang, V. Weigman, D. Wang, Y. Guan, L. Ryner, H. Koeppen, R. Patel, G. M. Hampton, L. C. Amler, Y. Wang, High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. *Clinical cancer research : an official journal of the American Association for Cancer Research* **20**, 2080-2091 (2014).
 26. L. Y. Huw, C. O'Brien, A. Pandita, S. Mohan, J. M. Spoerke, S. Lu, Y. Wang, G. M. Hampton, T. R. Wilson, M. R. Lackner, Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. *Oncogenesis* **2**, e83 (2013).
 27. T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D. P. Sutherland, H. Koeppen, M. Merchant, R. Neve, J. Settleman, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. *Nature* **487**, 505-509 (2012).
 28. O. Sakarya, H. Breu, M. Radovich, Y. Chen, Y. N. Wang, C. Barbacioru, S. Utiramerur, P. P. Whitley, J. P. Brockman, P. Vatta, Z. Zhang, L. Popescu, M. W. Muller, V.

- Kudlingar, N. Garg, C. Y. Li, B. S. Kong, J. P. Bodeau, R. C. Nutter, J. Gu, K. S. Bramlett, J. K. Ichikawa, F. C. Hyland, A. S. Siddiqui, RNA-Seq mapping and detection of gene fusions with a suffix array algorithm. *PLoS computational biology* **8**, e1002464 (2012).
29. L. C. Amler, Y. Wang, G. Hampton, HER2 as a Therapeutic Target in Ovarian Cancer. *Ovarian Cancer - Clinical and Therapeutic Perspectives Book Chapter*, (2012).
 30. T. Hung, Y. Wang, M. F. Lin, A. K. Koegel, Y. Kotake, G. D. Grant, H. M. Horlings, N. Shah, C. Umbricht, P. Wang, Y. Wang, B. Kong, A. Langerod, A. L. Borresen-Dale, S. K. Kim, M. van de Vijver, S. Sukumar, M. L. Whitfield, M. Kellis, Y. Xiong, D. J. Wong, H. Y. Chang, Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. *Nat Genet* **43**, 621-629 (2011).
 31. W. Cui, J. Ma, Y. Wang, S. Biswal, Plasma miRNA as biomarkers for assessment of total-body radiation exposure dosimetry. *PLoS One* **6**, e22988 (2011).
 32. S. Bandyopadhyay, R. C. Friedman, R. T. Marquez, K. Keck, B. Kong, M. S. Icardi, K. E. Brown, C. B. Burge, W. N. Schmidt, Y. Wang, A. P. McCaffrey, Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. *J Infect Dis* **203**, 1753-1762 (2011).
 33. F. Simunovic, M. Yi, Y. Wang, R. Stephens, K. C. Sonntag, Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. *PLoS One* **5**, e8856 (2010).
 34. A. G. Ooi, D. Sahoo, M. Adorno, Y. Wang, I. L. Weissman, C. Y. Park, MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. *Proc Natl Acad Sci U S A* **107**, 21505-21510 (2010).
 35. Y. C. Han, C. Y. Park, G. Bhagat, J. Zhang, Y. Wang, J. B. Fan, M. Liu, Y. Zou, I. L. Weissman, H. Gu, microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. *J Exp Med* **207**, 475-489 (2010).
 36. R. A. Gupta, N. Shah, K. C. Wang, J. Kim, H. M. Horlings, D. J. Wong, M. C. Tsai, T. Hung, P. Argani, J. L. Rinn, Y. Wang, P. Brzoska, B. Kong, R. Li, R. B. West, M. J. van de Vijver, S. Sukumar, H. Y. Chang, Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature* **464**, 1071-1076 (2010).
 37. Y. Wang, I. Russell, C. Chen, MicroRNA and stem cell regulation. *Curr Opin Mol Ther* **11**, 292-298 (2009).
 38. Y. Wang, D. N. Keys, J. K. Au-Young, C. Chen, MicroRNAs in embryonic stem cells. *J Cell Physiol* **218**, 251-255 (2009).
 39. F. Simunovic, M. Yi, Y. Wang, L. Macey, L. T. Brown, A. M. Krichevsky, S. L. Andersen, R. M. Stephens, F. M. Benes, K. C. Sonntag, Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. *Brain* **132**, 1795-1809 (2009).
 40. Y. Wang, B. C. S. R., Real-time PCR in biomarker development. *Book chapter in Biomarker Methods in Drug Discovery and Development*, (2008).
 41. S. Y. Chen, Y. Wang, M. J. Telen, J. T. Chi, The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. *PLoS One* **3**, e2360 (2008).
 42. Y. Wang, C. C. Barbacioru, D. Shiffman, S. Balasubramanian, O. Iakoubova, M. Tranquilli, G. Albornoz, J. Blake, N. N. Mehmet, D. Ngadimo, K. Poulter, F. Chan, R. R.

- Samaha, J. A. Eleftheriades, Gene expression signature in peripheral blood detects thoracic aortic aneurysm. *PLoS One* **2**, e1050 (2007).
43. Y. Wang, C. Barbacioru, F. Hyland, W. Xiao, K. L. Hunkapiller, J. Blake, F. Chan, C. Gonzalez, L. Zhang, R. R. Samaha, Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. *BMC Genomics* **7**, 59 (2006).
 44. S. J. Walker, Y. Wang, K. A. Grant, F. Chan, G. M. Hellmann, Long versus short oligonucleotide microarrays for the study of gene expression in nonhuman primates. *J Neurosci Methods* **152**, 179-189 (2006).
 45. T. Sorlie, Y. Wang, C. Xiao, H. Johnsen, B. Naume, R. R. Samaha, A. L. Borresen-Dale, Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. *BMC Genomics* **7**, 127 (2006).
 46. C. C. Barbacioru, Y. Wang, R. D. Canales, Y. A. Sun, D. N. Keys, F. Chan, K. A. Poulter, R. R. Samaha, Effect of various normalization methods on Applied Biosystems expression array system data. *BMC Bioinformatics* **7**, 533 (2006).
 47. C. Barbacioru, Y. Wang, R. Canales, R. Samaha, Comparison of different normalization methods for Applied Biosystems Expression Array System. *Book Chapter: Microarray Methods and Applications: Nuts & Bolts Edition 2*, (2006).
 48. Y. Wang, R. R. Samaha, From genes to diagnostics: integrating technology makes it possible. *Nature Methods* **2**, doi:10.1038 (2005).
 49. Y. Arava, Y. Wang, J. D. Storey, C. L. Liu, P. O. Brown, D. Herschlag, Genome-wide analysis of mRNA translation profiles in *Saccharomyces cerevisiae*. *Proc Natl Acad Sci U S A* **100**, 3889-3894 (2003).
 50. Y. Wang, C. L. Liu, J. D. Storey, R. J. Tibshirani, D. Herschlag, P. O. Brown, Precision and functional specificity in mRNA decay. *Proc Natl Acad Sci U S A* **99**, 5860-5865 (2002).
 51. Y. Wang, R. Gao, D. G. Lynn, Ratcheting up vir gene expression in *Agrobacterium tumefaciens*: coiled coils in histidine kinase signal transduction. *ChemBiochem* **3**, 311-317 (2002).
 52. Y. Wang, A. Mukhopadhyay, V. R. Howitz, A. N. Binns, D. G. Lynn, Construction of an efficient expression system for *Agrobacterium tumefaciens* based on the coliphage T5 promoter. *Gene* **242**, 105-114 (2000).
 53. A. M. Campbell, J. B. Tok, J. Zhang, Y. Wang, M. Stein, D. G. Lynn, A. N. Binns, Xenognosin sensing in virulence: is there a phenol receptor in *Agrobacterium tumefaciens*? *Chem Biol* **7**, 65-76 (2000).